• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从基于点击化学的组合文库的小型化中鉴定出高效且选择性的 Cdc25 蛋白磷酸酶抑制剂。

Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.

机构信息

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Ji'nan, Shandong, PR China.

Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, 4001, South Africa.

出版信息

Eur J Med Chem. 2019 Dec 1;183:111696. doi: 10.1016/j.ejmech.2019.111696. Epub 2019 Sep 14.

DOI:10.1016/j.ejmech.2019.111696
PMID:31541869
Abstract

Cell division cycle 25 (Cdc25) protein phosphatases play key roles in the transition between the cell cycle phases and their association with various cancers has been widely proven, which makes them ideal targets for anti-cancer treatment. Though several Cdc25 inhibitors have been developed, most of them displayed low activity and poor subtype selectivity. Therefore, it is extremely important to discover novel small molecule inhibitors with potent activities and significant selectivity for Cdc25 subtypes, not only served as drugs to treat cancer but also to probe its mechanism in transitions. In this study, miniaturized parallel click chemistry synthesis via CuAAC reaction followed by in situ biological screening were used to discover selective Cdc25 inhibitors. The bioassay results showed that compound M2N12 proved to be the most potent Cdc25 inhibitor, which also act as a highly selective Cdc25C inhibitor and was about 9-fold potent than that of NSC 663284. Moreover, M2N12 showed remarkable anti-growth activity against the KB-VIN cell line, equivalent to that of PXL and NSC 663284. An all-atom molecular dynamics (MD) simulation approach was further employed to probe the significant selectivity of M2N12 for Cdc25C relative to its structural homologs Cdc25A and Cdc25B. Overall, above results make M2N12 a promising lead compound for further investigation and structural modification.

摘要

细胞分裂周期蛋白 25(Cdc25)蛋白磷酸酶在细胞周期各阶段的转换中发挥着关键作用,其与各种癌症的关联已得到广泛证实,这使其成为抗癌治疗的理想靶点。尽管已经开发出几种 Cdc25 抑制剂,但它们大多数活性低且对亚型的选择性差。因此,发现具有强活性和对 Cdc25 亚型显著选择性的新型小分子抑制剂非常重要,不仅可作为治疗癌症的药物,还可用于探究其在转换中的作用机制。在本研究中,采用 CuAAC 反应的微型化平行点击化学合成,随后进行原位生物筛选,用于发现选择性 Cdc25 抑制剂。生物测定结果表明,化合物 M2N12 被证明是最有效的 Cdc25 抑制剂,也是一种高选择性的 Cdc25C 抑制剂,其活性比 NSC 663284 高约 9 倍。此外,M2N12 对 KB-VIN 细胞系表现出显著的抗增殖活性,与 PXL 和 NSC 663284 相当。进一步采用全原子分子动力学(MD)模拟方法探究了 M2N12 对 Cdc25C 的显著选择性,与结构同源物 Cdc25A 和 Cdc25B 相比。总体而言,上述结果使 M2N12 成为进一步研究和结构修饰的有前途的先导化合物。

相似文献

1
Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.从基于点击化学的组合文库的小型化中鉴定出高效且选择性的 Cdc25 蛋白磷酸酶抑制剂。
Eur J Med Chem. 2019 Dec 1;183:111696. doi: 10.1016/j.ejmech.2019.111696. Epub 2019 Sep 14.
2
Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries.通过快速组装和原位筛选醌类化合物库发现有效的和选择性的 Cdc25 磷酸酶抑制剂。
Bioorg Chem. 2021 Oct;115:105254. doi: 10.1016/j.bioorg.2021.105254. Epub 2021 Aug 9.
3
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.双特异性蛋白磷酸酶Cdc25新型强效抑制剂家族的发现及生物学评价
J Med Chem. 2001 Nov 22;44(24):4042-9. doi: 10.1021/jm0102046.
4
Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.基于配体的化学信息学方法发现一种新型小分子抑制剂,该抑制剂靶向细胞周期蛋白依赖性激酶25双特异性磷酸酶,并对黑色素瘤细胞具有体外抑制活性。
Oncotarget. 2015 Nov 24;6(37):40202-22. doi: 10.18632/oncotarget.5473.
5
Effective Pharmacophore for CDC25 Phosphatases Enzyme Inhibitors: Newly Synthesized Bromothiazolopyrimidine Derivatives.靶向 CDC25 磷酸酶的有效药效团:新型合成的溴噻唑并嘧啶衍生物。
Mini Rev Med Chem. 2021;21(1):118-131. doi: 10.2174/1389557520666200619182519.
6
Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies.基于结构的新型三唑和相关噻唑并三唑类抗癌药物和 Cdc25A/B 磷酸酶抑制剂的开发。合成、体外生物学评价、分子对接和计算机 ADME-T 研究。
Eur J Med Chem. 2017 Oct 20;139:263-279. doi: 10.1016/j.ejmech.2017.07.053. Epub 2017 Jul 25.
7
Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.1,4-萘醌类化合物的合成、抗癌活性及抑制 MKK7 和 Cdc25 的分子模拟。
Eur J Med Chem. 2019 Dec 1;183:111719. doi: 10.1016/j.ejmech.2019.111719. Epub 2019 Sep 18.
8
Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases.新型香豆素类 Cdc25 磷酸酶抑制剂的合成与生物评价。
Bioorg Med Chem Lett. 2010 Oct 1;20(19):5827-30. doi: 10.1016/j.bmcl.2010.07.130. Epub 2010 Aug 3.
9
Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.新型咪唑并吡啶衍生物CHEQ-2作为一种有效的细胞周期蛋白依赖性激酶25(CDC25)抑制剂及有前景的抗癌药物候选物的发现与表征
Eur J Med Chem. 2014 Jul 23;82:293-307. doi: 10.1016/j.ejmech.2014.05.063. Epub 2014 May 27.
10
Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.基于结构的虚拟筛选发现 Cdc25B 双特异性磷酸酶的新抑制剂。
J Med Chem. 2012 May 10;55(9):4142-58. doi: 10.1021/jm201624h. Epub 2012 May 1.

引用本文的文献

1
PSP205, a Novel Phenyl Sulfonyl Piperidine, Induces Apoptotic Cell Death in Colon Cancer by Modulating Coat Protein Complex-Mediated Vesicle Trafficking.PSP205,一种新型苯基磺酰基哌啶,通过调节衣被蛋白复合物介导的囊泡运输诱导结肠癌细胞凋亡。
ACS Pharmacol Transl Sci. 2025 Jan 9;8(4):1072-1086. doi: 10.1021/acsptsci.4c00617. eCollection 2025 Apr 11.
2
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer.新型双重抑制剂靶向 CDC25 和 HDAC 治疗三阴性乳腺癌。
Apoptosis. 2024 Dec;29(11-12):2047-2073. doi: 10.1007/s10495-024-02023-7. Epub 2024 Oct 12.
3
Scaffold Hopping and Structural Modification of NSC 663284: Discovery of Potent (Non)Halogenated Aminobenzoquinones.
NSC 663284的骨架跃迁与结构修饰:新型(非)卤代氨基苯醌的发现
Biomedicines. 2023 Dec 24;12(1):50. doi: 10.3390/biomedicines12010050.
4
Programmed cell death 11 modulates but not entirely relies on p53-HDM2 loop to facilitate G2/M transition in colorectal cancer cells.程序性细胞死亡蛋白11调节但并非完全依赖p53-HDM2环来促进结肠癌细胞的G2/M期转换。
Oncogenesis. 2023 Dec 7;12(1):57. doi: 10.1038/s41389-023-00501-2.
5
Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors click-chemistry-based rapid screening.新型1,2,3-三唑异吲哚酮衍生物作为强效严重急性呼吸综合征冠状病毒2 3C样蛋白酶抑制剂的鉴定:基于点击化学的快速筛选
RSC Med Chem. 2023 Aug 17;14(10):2068-2078. doi: 10.1039/d3md00306j. eCollection 2023 Oct 18.
6
Menadione: a platform and a target to valuable compounds synthesis.甲萘醌:一种用于合成有价值化合物的平台和目标。
Beilstein J Org Chem. 2022 Apr 11;18:381-419. doi: 10.3762/bjoc.18.43. eCollection 2022.